BridgeBio Pharma (BBIO) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for BridgeBio Pharma (BBIO) over the last 6 years, with Q3 2025 value amounting to -$0.95.
- BridgeBio Pharma's EPS (Weighted Average and Diluted) fell 1046.51% to -$0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.2, marking a year-over-year decrease of 7427.39%. This contributed to the annual value of -$2.88 for FY2024, which is 2710.72% up from last year.
- According to the latest figures from Q3 2025, BridgeBio Pharma's EPS (Weighted Average and Diluted) is -$0.95, which was down 1046.51% from -$0.95 recorded in Q2 2025.
- In the past 5 years, BridgeBio Pharma's EPS (Weighted Average and Diluted) ranged from a high of -$0.07 in Q2 2022 and a low of -$1.42 during Q4 2024
- In the last 5 years, BridgeBio Pharma's EPS (Weighted Average and Diluted) had a median value of -$0.94 in 2022 and averaged -$0.87.
- Per our database at Business Quant, BridgeBio Pharma's EPS (Weighted Average and Diluted) surged by 8939.39% in 2022 and then crashed by 130000.0% in 2023.
- Quarter analysis of 5 years shows BridgeBio Pharma's EPS (Weighted Average and Diluted) stood at -$1.02 in 2021, then grew by 9.76% to -$0.92 in 2022, then dropped by 4.35% to -$0.96 in 2023, then crashed by 48.38% to -$1.42 in 2024, then skyrocketed by 33.31% to -$0.95 in 2025.
- Its last three reported values are -$0.95 in Q3 2025, -$0.95 for Q2 2025, and -$0.88 during Q1 2025.